As such, we encourage the FDA to continue to apply distinct names for future biosimilars, and to maximize clarity in the labeling of biosimilars, specifically with respect to their interchangeable status and the origins (reference drug versus biosimilar) of clinical data upon which FDA approval is based. (sciencedaily.com)
D.C. is included too (since the SSA throws their top 100 in the state section), which is great because its inhabitants have their own distinct naming style! (feedspot.com)
«The ACR supports distinct naming and transparent labeling for all biosimilar products to ensure correct prescribing and dispensing, post-marketing surveillance, prescriber confidence, and enhanced market uptake. (sciencedaily.com)